Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

Immix Biopharma is advancing NXC-201, showing 95% complete/near-complete response rates and superior safety. Learn why IMMX ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for ...

The FDA drug center’s new acting director Tracy Beth Høeg fits a pattern of risky, internal contradictions among agency ...

A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

With a SIM-swapping attack, scammers hijack your phone number to gain access to apps on your phone—including banking apps.

Nayra Guzmán was arrested 15 days after her daughter’s difficult birth. Before Trump took office, postpartum immigrants were ...

Ovarian cancer tends to be resistant to hormone therapy, even when it should theoretically respond. Wistar Institute ...

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top ...

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...